Inhaled Tranexamic Acid for Pulmonary Hemorrhage in Cancer Patients
This study is testing if inhaled tranexamic acid can help cancer patients who are experiencing pulmonary hemorrhage (bleeding in the lungs) and need a breathing machine. Researchers will compare inhaled tranexamic acid to usual care (standard treatment) to see if it improves survival within 28 days. You might be able to join if you are over 18, have a blood cancer, are on a breathing machine, and have signs of bleeding in your lungs. The study aims to enroll 60 patients. The current recruitment status is unclear.
- Study design
- This is a randomized controlled trial, meaning participants will be assigned by chance to receive either inhaled tranexamic acid or usual care. The study plans to enroll 60 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goal is to measure survival up to 28 days after treatment. Other outcomes will be tracked for up to 100 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nisha Rathi, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- 28 day all-cause mortality rateup to 28 days
Number of patients who are alive at 28 days following randomization. The difference between 28-day mortality rates between treatment arms will be computed along with a 95% confidence interval (CI) using the approximate standard error reported in Fleiss (1981). Logistic regression will be used to estimate the association between 28-day mortality and study covariates of interest.